hapabapa Moderna (NASDAQ:MRNA) on Tuesday announced a $176M contract from the U.S. government to accelerate the development of messenger-RNA-based vaccines targeting several influenza strains, including the bird flu family of viruses. The company said that the funding channeled through the Biomedical Advanced Research and Development Authority (BARDA) is expected toContinue Reading
designer491/iStock via Getty Images Valneva (NASDAQ:VALN) shares jumped 8.4% premarket on Monday after the vaccine company secured marketing authorization in Europe for its chikungunya vaccine, Ixchiq. Ixchiq is the world’s only licensed chikungunya vaccine and has been approved for the prevention of disease caused by the chikungunya virus in individualsContinue Reading
Erik S. Lesser/Getty Images News Merck (NYSE:MRK) announced that a group of independent advisors to the U.S. CDC unanimously voted to recommend its newly approved pneumonia vaccine, Capvaxive, for adults aged 65 years and older. The decision comes days after the FDA approved the 21-valent conjugate vaccine for preventing invasiveContinue Reading
